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We investigated the feasibility of bacteriophage therapy to combat canine and feline Escherichia coli urinary tract infections (UTIs) by
testing the in vitro lytic ability of 40 naturally occurring bacteriophages on 53 uropathogenic E. coli (UPEC). The mean number of UPEC
strains lysed by an individual bacteriophage was 21/53 (40%, range 17–72%). In total, 50/53 (94%) of the UPEC strains were killed by one
or more of the bacteriophages. Ten bacteriophages lysed P51% of UPEC strains individually and 92% of UPEC strains as a group.
Electron microscopy and DNA sequencing of 5 ‘promising’ bacteriophages revealed that 4 bacteriophages belonged to the lytic T4-like
genus, while one displayed morphologic similarity to temperate P2-like bacteriophages. Overall, these results indicate that the majority of
UPEC are susceptible to lysis by naturally occurring bacteriophages. Thus, bacteriophages show promise as therapeutic agents for treat-
ment of canine and feline E. coli UTIs.
 2007 Elsevier Ltd. All rights reserved.
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Uropathogenic Escherichia coli (UPEC) is the most
important infectious cause of urinary tract disease in dogs,
cats and people (Foxman, 2002; Ling, 2000; Russo and
Johnson, 2003). UPEC infections, once diagnosed, are usu-
ally managed with antibiotic therapy (Bartges, 2005). How-
ever, antibiotic resistant forms of UPEC have emerged and
pose problems in many parts of the world (Cohn et al.,
2003; Manges et al., 2001; Mulvey et al., 2001). Even
UPEC that are susceptible to antibiotics in vitro may per-
sist in an infected host, or in its immediate environment,
despite lengthy antibiotic treatment (Freitag et al., 2006;
Schilling et al., 2002; Seguin et al., 2003). In dogs and cats,0034-5288/$ - see front matter  2007 Elsevier Ltd. All rights reserved.
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E-mail address: Thurid.Freitag@ucd.ie (T. Freitag).persistence or relapse of urinary tract infections (UTIs) has
recently been shown to occur more often than had previ-
ously been realised (Drazenovich et al., 2004; Freitag
et al., 2006). When persistence or relapse is recognised,
antibiotic therapy is often extended. However, it is some-
times difficult to cure affected patients. Therapy with bacte-
riophages (phages) – viruses that can infect and kill
bacteria – may be used to supplement or substitute antibi-
otic therapy (Alisky et al., 1998). Phage therapy of human
UTIs dates back to early last century (reviewed by Raettig,
1958). In more recent years, phages have been used success-
fully to prevent or cure E. coli meningitis, pneumonia and
gastroenteritis in chicken, mice and calves (Barrow et al.,
1998; Huff et al., 2003, 2004; Smith and Huggins, 1982,
1983). Furthermore, recent clinical observations from the
former Soviet Union and Poland indicate that phages can
be used successfully to resolve antibiotic resistant UTIs in
humans (Perepanova et al., 1995; Slopek et al., 1987;
Weber-Dabrowska et al., 2000). These clinical observations
and experimental studies are encouraging. Nonetheless, the
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ticularly in dogs and cats, remains to be investigated.
In this study, we tested the hypothesis that a variety of
phages able to lyse canine and feline UPEC can readily
be found in the environment. The ability of collected
phages to cause lysis in vitro was tested on 53 UPEC strains
and 7 faeces-derived E. coli strains from dogs and cats.
When lysis profiles suggested that phages were promising
candidates for an in vivo trial, phages were subjected to fur-
ther morphological and genetic studies, using electron
microscopy and DNA sequencing.
2. Materials and methods
2.1. Strain collection
Between January 2002 and April 2004, 31 UPEC strains
from dogs and 22 UPEC strains from cats were obtained
from 4 New Zealand animal health laboratories. Each
strain was cultured from urine derived from individual ani-
mals at a different place or time. Urine collection was done
by antepubic cystocentesis, a method previously shown to
minimise contamination with cutaneous and faecal organ-
isms (Comer and Ling, 1981). Fifty-one of these strains,
which were assessed further by molecular means, differed
either in possession of virulence factor gene markers,
Pulsed-Field Gel Electrophoresis banding patterns or both
(Freitag et al., 2005). The genomes of the 2 remaining
UPEC strains were not assessed. However, the UPEC
strains are likely to be epizootiologically unrelated. They
were isolated 14 months apart from a dog and a cat, respec-
tively, that lived in different geographic regions of New
Zealand. Seven faecal E. coli isolates were collected from
stool samples of 4 dogs and 3 cats without clinical signs
of UTI or gastrointestinal disease. After acquisition, all
UPEC and faecal E. coli isolates were biochemically con-
firmed to belong to the species E. coli (Quinn et al.,
1994). Isolates were stored in 15% glycerol broth at
70 C until use.
2.2. Preparation of phage stocks
Phages were isolated from Palmerston North sewage
according to a method published by Biswas et al. (2002),
using centrifugation, polyethylene glycol (PEG) 8000 pre-
cipitation, chloroform extraction and propagation on
selected UPEC strains. Propagation of phages was initially
performed on 21 canine and 21 feline UPEC, chosen at
random, using the double-layer technique (Ackermann
and DuBow, 1987). In detail, a 100 ll aliquot of processed
sewage was added to a 100 ll aliquot of each selected
E. coli culture, grown in Luria Bertani (LB) broth at
37 C overnight. After incubation for 20 min at 37 C,
the mixture was added to 2 ml molten LB top agar (LB
broth containing 0.65% agarose, kept at 50 C until use),
mixed gently and poured onto 55 mm LB agar plates. After
overnight incubation at 37 C, one well-separated phageplaque was picked from each plate that displayed plaques.
Each of the picked plaques was separately suspended in
1 ml SM buffer (Sambrook and Russell, 2001). Harvested
phages were plaque purified on their target E. coli isolates
by repeating the double-layer technique 2 more times,
using the newly obtained phage suspension instead of pro-
cessed sewage. Small-scale liquid cultures and large-scale
lysates of purified phages were prepared according to stan-
dard methods (Sambrook and Russell, 2001). Subse-
quently, phage stock solutions were prepared by PEG
precipitation and chloroform extraction of large-scale
phage lysates (Sambrook and Russell, 2001). Phage stock
titres were determined by serial dilution and plaque assay,
counting the plaque-forming units on the strain on which
they had been propagated (Ackermann and DuBow,
1987). Stocks containing P107 phages/ml were considered
appropriate for further analysis. Phage stocks were stored
in 10 ml SM buffer aliquots containing 1% (v/v) chloro-
form at 4 C until further use.
2.3. Bacteriophage lysis
The lysis experiment was designed to test the ability of
phages to lyse strains from the E. coli collection. Each
phage was tested separately on each bacterial strain in
the collection. LB broth cultures of all bacterial strains of
the collection (53 UPEC and 7 faecal E. coli) were prepared
according to standard methods (Quinn et al., 1994). Lysis
was initially tested using a modified macroplaque technique
(MMT; Sambrook and Russell, 2001). In detail, 200 ll of
each E. coli culture in turn was mixed with 1 ml molten
LB top agar and plated onto a layer of LB agar. Phages
were transferred from the phage stock solution to the
freshly plated culture using sterile wooden toothpicks.
The toothpicks were dipped into phage stock solution,
gently swirled to allow adherence of phage particles, and
pierced several times into the freshly plated bacterial cul-
ture. After overnight incubation at 37 C, plates were
checked for evidence of clear zones of lysis around the
toothpick marks. When lysis was present, a positive result
was declared. The MMT was compared with the standard
double-layer plating technique (see above) on 30 randomly
chosen bacterial cultures. Positive results of the MMT were
100% in accord with results of the standard plating tech-
nique. When a zone of lysis was not clearly visible using
the MMT (i.e. lysis 61 mm around the toothpick mark),
the phage’s ability to lyse the bacterial strain was further
tested using a standard double-layer plating procedure.
After overnight incubation at 37 C, plates were observed
for presence or absence of plaques. When plaques were
present, a positive result was declared. Absence of plaques
was interpreted as a negative result.
2.4. Electron microscopy (EM)
EM was performed on 5 phages selected from the phage
collection on the basis of a promising lysis profile. A stan-
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bration. Ten ml of the respective phage stock solutions
was concentrated by ultracentrifugation at 30,000g for
2 h at 4 C (SS 34 rotor, Sorvall RC 5C, Thermo EC, Wal-
tham, MA, USA). Phage pellets were carefully resuspended
in 1 ml SM buffer, and kept on ice until EM was per-
formed. For each phage EM study, 1 drop of the prepared
phage concentrate was placed on Parafilm M (Brand Sci-
entific Pty Ltd., Silverwater, NSW, Australia). A formvar-
carbon-coated copper grid (200 mesh, Agar Brand, Agar
Scientific, Stansted, Essex, UK) was floated on top of the
phage concentrate for 4.5–6 min, blotted dry and stained
with 2% uranyl acetate (UA; pH 4.2) or phosphotungstate
(pH 7.0) for 4.5–6 min. The copper grid was blotted dry
and studied under a Philips 201C transmission electron
microscope (Philips, Eindhoven, Holland) using an acceler-
ating voltage of 60 kV. For each of the 5 selected phage
strains and the T4 control, phage size was obtained by
averaging measurements of >20 phage particles photo-
graphed at a magnification of 72,100 · normal size. Mea-
sured sizes were compared with published sizes for T4
(Bu¨chen-Osmond, 2006).
2.5. Sequencing of bacteriophage DNA fragments
Four phages that morphologically resembled T4-like
phages were subjected to PCR analysis and DNA sequenc-
ing of the amplified tail tube glycoprotein gene 18 fragment
to compare these phages to phylogenetically well-charac-
terised phages (Tetart et al., 2001). Bacteriophage DNA
was extracted and purified from stock concentrates using
a commercial phage DNA extraction kit (Qiagen Pty
Ltd., Doncaster, Victoria, Australia). PCR was done in a
25 ll reaction volume containing 2 mM MgSO4, 0.2 mM
each dNTP, 0.4 lM of each primer FT18-N2 and FT18-
C3 (Tetart et al., 2001), 1· buffer, 1 U Platinum Pfx
DNA Polymerase (Invitrogen, Auckland, NZ) and 50 ng
template DNA. Cycling consisted of initial denaturation
(2 min at 94 C) followed by a primary cycle period
(10 · {30 s at 94 C; 15 s at 58 C; 50 s at 68 C}), a second-
ary cycle period (20 · {30 s at 94 C; 15 s at 56 C; 45 s at
68 C}) and a final extension (2 min at 68 C). The ampli-
fied DNA fragment was separated by gel electrophoresis,
excised from the gel and purified using a commercial gel
extraction kit (Qiagen Pty Ltd., Doncaster, Victoria, Aus-
tralia). To increase the yield of phage DNA for sequencing
purposes, the PCR reaction was repeated in a second round
using the purified DNA fragment as template. Subse-
quently, DNA fragments were purified with a PCR purifi-
cation kit (Qiagen Pty Ltd., Doncaster, Victoria,
Australia). Sequencing was done with an ABI 3730 Genetic
Analyzer, using a BigDye Terminator Version 3.1 Ready
Reaction Cycle Sequencing kit (Applied Biosystems Inc.,
Foster City, CA, USA). Obtained nucleotide sequences
were compared with previously published nucleotide
sequences of phages that had been characterised in a previ-
ous phylogenetic study (Tetart et al., 2001). To displayrelationships between the sequences, a neighbour-joining
tree was created using the Clustal-W aligned sequences
(Chenna et al., 2003) using the software PAUP* 4.0 (Swof-
ford, 2003).
2.6. Statistical analysis
The z-test of proportions was used to test whether the
proportion undergoing lysis was related to the category
of E. coli (i.e. UPEC or faecal E. coli; Dawson and Trapp,
1994). Results of z-test were adjusted for problems of mul-
tiplicity using Holm’s step-down procedure (Ludbrook,
1998).
2.7. Nucleotide sequence accession numbers
The nucleotide sequences of the central portion of gene
18 from phages 1–4 have been deposited in the GenBank
database under accession numbers DQ647771-DQ647774.
3. Results
3.1. Phage isolation
Phage isolation was attempted from processed sewage
using 21 canine and 21 feline UPEC strains. Plaques were
observed on 40 of the 42 UPEC strains after overnight
incubation. No plaques formed on two of the canine UPEC
strains.
3.2. High susceptibility of UPEC to phage
Each phage had a unique host range. Individual phages
lysed a mean of 21.2/53 (40%) UPEC strains in the collec-
tion (range 17–70%, median 38%). The 10 phages with the
broadest host range each lysed at least 27/53 (51%) of the
UPEC strains (Fig. 1). Twelve UPEC strains (5 canine
and 7 feline) were lysed by all of these 10 phages. As a
group, the 10 phages with the broadest host range lysed
49/53 (92%) UPEC strains. All but 3 of the 53 UPEC
strains (6%) could be killed by at least one of the 40 phages
in the collection. These 3 UPEC strains, which originated
from dogs, comprised 2 strains that yielded no plaques
after initial incubation with sewage and 1 additional strain
that was not used in the initial preparation of phage stocks.
3.3. Relatively low susceptibility of faecal E. coli to phage
The phage susceptibility of 7 E. coli strains isolated from
normal faeces was tested to investigate whether phages able
to lyse UPEC were also able to lyse faecal E. coli strains
presumed to be commensal. The 40 phages lysed on aver-
age 0.9/7 (13%) faecal E. coli strains (range 0–71%, median
14%). Lysis of faecal E. coli strains was significantly less
likely than lysis of UPEC strains (Holm’s adjusted z test,
P = 0.001). The susceptibility of faecal E. coli to the 10
phages that lysed the most UPEC strains was similar to
Fig. 1. Illustration of characteristics of UPEC strains and their lysis by the 10 phages with the broadest host range. (a) Species UPEC strain was isolated
from: C: canine, F: feline. (b) Differences in lysis between 10 selected phages: d indicates that lysis was observed, a space indicates that no lysis was
observed. s indicates that the phage was isolated from above UPEC strain. (c) Differences in lysis between the 10 phages were observed in 53 UPEC
strains.
4 T. Freitag et al. / Research in Veterinary Science 85 (2008) 1–7the susceptibility to the 30 other members of the phage col-
lection. Of the 10 phages with the broadest UPEC host
range, 7 (phages 3, 4, 5, 7, 15, 25 and 38) lysed 1/7 faecal
E. coli, one (phage 33) lysed 2/7 faecal E. coli, and 2
(phages 1 and 2) lysed 3/7 faecal E. coli. Compared to other
faecal E. coli that were lysed by 66/40 phages, one faecal
E. coli strain (Strain 135) appeared particularly susceptible
to the phages in the collection. Considering once again the
10 phages with the broadest UPEC host range, strain 135
was lysed by 5 of the 7 that lysed a single faecal strain
and by both of those that lysed 3/7 faecal strains. Strain
135 was also lysed by 6 of the other 30 phages in the
collection.Fig. 2. Electron microscopic images of phages 1–5 (from left to right).
measurement · side measurement. (b) Tail size, length · width.3.4. Characterisation of 5 ‘promising’ phages
Five phages (1–5) that showed a broad host range, lys-
ing P53% UPEC isolates (Fig. 1), were characterised fur-
ther. Electron microscopy revealed that all of these
phages belonged to the order Caudovirales and the family
Myoviridae (Bu¨chen-Osmond, 2006). Phages 1–4 belonged
to the morphotype A2 (Ackermann and Eisenstark, 1974)
and had morphological similarity to lytic phage T4
(Fig. 2; Bu¨chen-Osmond, 2006). These morphological find-
ings were verified by sequence analysis. For each of the
four T4-like phages a tail gene could be amplified using
primers based on the T4 tail gene 18 (Tetart et al., 2001).UA staining. The white bar indicates 100 nm. (a) Head size, apical
Fig. 3. Comparison of phages 1–4 to phylogenetically well-characterised
phages (Tetart et al., 2001). Accession numbers of gene sequences that
were obtained from GenBank are given in brackets.
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each other. When comparing the tail gene sequences with
sequences of 7 phylogenetically well-characterised T4-like
phages (Tetart et al., 2001), these phages clustered closely
with others belonging to the T-even group (T4 and
RB69; Fig. 3). Phage 5 had a different morphology to
phages 1–4 (Fig. 2). It belonged to the morphotype A1
(Ackermann and Eisenstark, 1974) and had morphological
similarity to temperate phage P2 (Bu¨chen-Osmond, 2006).
However, the tail of phage 5 appeared considerably longer
than previously reported for P2 phages (Bu¨chen-Osmond,
2006).
4. Discussion and conclusions
This study showed that naturally occurring phages,
readily obtained by making a single visit to a sewage treat-
ment plant, were able to lyse a large proportion of the
canine and feline UPEC strains in our collection, at least
in vitro. Individual phages were able to kill 17–72% of the
UPEC strains in our collection. The 10 phages with the
broadest host range each lysed more than half of all UPEC
strains. Each of them had a distinct lysis profile and, taken
together, they lysed 92% of the UPEC strains. This result is
in marked contrast to a previously published study of
E. coli UTIs in children (Drulis-Kawa et al., 2002), in
which only 14 of 44 phages lysed more than 15% of the
UPEC strains studied. Only 3 phages studied by Drulis-
Kawa et al. (2002) lysed more than 50% of UPEC strains.
Phages used in the previous study were selected from a hos-
pital collection of E. coli phages. It is possible that our
selective propagation of phages on UPEC improved our
overall lysis results. However, it cannot be excluded at this
stage that UPEC isolated from cats and dogs are, in gen-
eral, more susceptible to phage lysis than are UPEC iso-
lated from children.
Our results indicate that it may be possible to treat UTIs
caused by a large variety of UPEC strains with one prepa-ration containing a mixture of phages that have, overall, a
relatively broad host range. Previous applications of such
phage combinations (so-called ‘phage cocktails’) in other
disorders have been described as highly successful (Kutter
and Sulakvelidze, 2005). The use of a ‘cocktail’ may not
only increase the proportion of UPEC strains that can be
lysed, and minimize the development of resistance to
phages, but it may also allow recombination of adhesin
structures (Kutter et al., 1995, 2005; Tetart et al., 1998).
Thus, new, ‘‘naturally recombinant’’ phages with an
extended host range may be created (Abe et al., 2007).
One of the concerns when using naturally occurring
phages is that these phages may have the ability to transfer
potentially deleterious genes to bacteria (Boyd and Brus-
sow, 2002; Wagner and Waldor, 2002). These so-called
transducing phages are almost exclusively temperate, that
is, they have the ability to integrate their genome into the
host bacterial genome (Birge, 2000). In addition to their
transducing potential, temperate phages are considered
inappropriate for phage therapy because these phages
may not lyse bacteria consistently (Lwoff, 1953). In this
study, EM and DNA sequencing of a tail tube gene were
applied to 5 phages with a promising lysis profile to inves-
tigate whether these naturally occurring phages are compa-
rable to previously studied lytic or temperate phages. Four
of these 5 phages were demonstrated to be T4-like (Bu¨chen-
Osmond, 2006), belonging to the T-even phage group
(Tetart et al., 2001). These 4 phages are considered to be
lytic phages that are unable to integrate their viral genome
into the host bacterial genome. Therefore, they are consid-
ered suitable candidates for future in vivo therapeutic trials
and suitable candidates for inclusion in ‘phage cocktails’. A
fifth phage with a very promising lysis profile that had a
morphotype similar to temperate phage P2 is at present
considered an inappropriate candidate for inclusion in
the therapeutic phage preparations. Inclusion in future
phage cocktails may be considered if subsequent studies
can show that this phage: (i) lyses UPEC consistently;
and (ii) does not encode deleterious traits.
Several previous studies have shown that phages readily
cross physiological barriers, irrespective of the route of
administration. (Biswas et al., 2002; Dubos et al., 1943;
Geier et al., 1973; Reynaud et al., 1992; Smith and Hug-
gins, 1982; Weber-Dabrowska et al., 1987). The ability of
phages to disperse within virtually all body compartments
is thought to facilitate oral phage therapy of UTIs
(Weber-Dabrowska et al., 1987). However, achievement
of therapeutic phage titres at distant sites of infection
may be challenging after oral phage administration. The
ability of phages to disperse throughout the body also
increases the likeliness that ‘therapeutic’ phages, even when
administered parenterally, will encounter and perhaps lyse
commensal gastrointestinal bacteria. Recent studies in mice
(Chibani-Chennoufi et al., 2004) and humans (Bruttin and
Brussow, 2005) indicate that commensal bacteria suscepti-
ble to phages in vitro are in vivo largely resistant to orally
administered phages. Nonetheless, it was considered desir-
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E. coli strains in vitro. Phages tested during this in vitro trial
lysed significantly more UPEC strains than faecal E. coli
strains. In fact, only one of the faecal strains tested showed
a phage susceptibility that was comparable to the average
susceptibility of UPEC. A likely explanation for this differ-
ence in susceptibility to lysis is that significantly more
UPEC than faecal E. coli expressed the specific receptors
necessary for phage attachment. The faecal strains were
isolated from animals without signs of gastrointestinal dis-
ease or UTI, and it is considered likely that most of them
were gastrointestinal commensals. Commensal E. coli and
UPEC commonly belong to different phylogenetic groups
and faecal E. coli strains often lack virulence traits that
are present in UPEC (Johnson et al., 2003; Johnson and
Russo, 2002; Whittam et al., 1989). By propagation of
phage on UPEC we may have selected for phages that rec-
ognise receptors selectively expressed by UPEC, but not by
commensal (faecal) E. coli.
In conclusion, this study has shown that a diversity of
phages able to lyse clinically-relevant canine and feline
UPEC isolates, at least in vitro, can readily be found in nat-
ure. Phage therapy of canine and feline UTIs – and of other
serious diseases caused by UPEC strains and their close rel-
atives – may therefore be feasible. Further work is needed
to investigate whether these in vitro findings translate into
clinically relevant in vivo efficacy.Acknowledgements
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